KROS

Keros Therapeutics, Inc. [KROS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

KROS Stock Summary

Top 10 Correlated ETFs

KROS


Top 10 Correlated Stocks

KROS


In the News

09:51 29 Mar 2024 KROS

Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable

Keros Therapeutics, Inc. (KROS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

10:56 29 Mar 2024 KROS

Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?

The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 35.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

09:51 29 Mar 2024 KROS

Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why

Keros Therapeutics, Inc. (KROS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

10:56 29 Mar 2024 KROS

Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know

The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 45.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

08:00 29 Mar 2024 KROS

Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress

LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that three abstracts will be presented from the KER-012 program at the Pulmonary Vascular Research Institute (“PVRI”) 2024 Annual Congress, to be held from January 31 through February 3, 2024.

09:50 29 Mar 2024 KROS

Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why

Keros Therapeutics, Inc. (KROS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

10:56 29 Mar 2024 KROS

Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy?

From a technical perspective, Keros Therapeutics, Inc. (KROS) is looking like an interesting pick, as it just reached a key level of support. KROS's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

08:00 29 Mar 2024 KROS

Keros Therapeutics to Present at Upcoming Healthcare Conferences

LEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:

04:01 29 Mar 2024 KROS

Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

LEXINGTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors.

08:00 29 Mar 2024 KROS

Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that Keros will host a conference call and webcast to provide an overview of TROPOS, its global Phase 2 clinical trial to evaluate KER-012 in combination with background therapy in patients with pulmonary arterial hypertension (“PAH”), on August 8, 2023 at 8:00 a.m. Eastern time.

KROS Financial details

Company Rating
Neutral
Market Cap
2.37B
Income
-149.93M
Revenue
151K
Book val./share
11.03
Cash/share
10.99
Dividend
-
Dividend %
-
Employees
136
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-10.96
Forward P/E
-12.2
PEG
-4.84
P/S
192826.19
P/B
5.16
P/C
6.01
P/FCF
-12.57
Quick Ratio
17.29
Current Ratio
18.23
Debt / Equity
0.04
LT Debt / Equity
0.04
-
-
EPS (TTM)
-5.09
EPS next Y
-5.42
EPS next Q
-1.36
EPS this Y
25.3%
EPS next Y
6.56%
EPS next 5Y
-139.13%
EPS last 5Y
50.21%
Revenue last 5Y
-56.77%
Revenue Q/Q
1687.5%
EPS Q/Q
0.75%
-
-
-
-
SMA20
1.24%
SMA50
28.17%
SMA100
130.43%
Inst Own
58.62%
Inst Trans
0.74%
ROA
-43%
ROE
-44%
ROC
-0.5%
Gross Margin
100%
Oper. Margin
-1943075%
Profit Margin
-1742550%
Payout
-
Shs Outstand
35.98M
Shs Float
26.71M
-
-
-
-
Target Price
112.5
52W Range
27.02-73.0
52W High
-9.45%
52W Low
+144.81%
RSI
53.12
Rel Volume
0.43
Avg Volume
463.24K
Volume
197.03K
Perf Week
2.96%
Perf Month
11.84%
Perf Quarter
101.28%
Perf Half Y
105.79%
-
-
-
-
Beta
1.281
-
-
Volatility
1.23%, 3.12%
Prev Close
2.23%
Price
66.1
Change
11.66%

KROS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.5500.8600.01
Net income per share
-0.68-2.93-2.52-4.15-5.2
Operating cash flow per share
-0.88-2.38-2.66-2.78-4.23
Free cash flow per share
-0.89-2.4-2.71-2.82-4.31
Cash per share
0.3917.159.8611.0611.25
Book value per share
0.316.8810.4210.9911.28
Tangible book value per share
0.316.8810.4210.9911.28
Share holders equity per share
0.316.8810.4210.9911.28
Interest debt per share
0.070.060.050.530.49
Market cap
365.24M1.09B1.37B1.21B1.17B
Enterprise value
359.5M828.84M1.14B946.29M854.11M
P/E ratio
-29.59-24.11-23.24-11.58-7.65
Price to sales ratio
36.52067.9207.75K
POCF ratio
-22.83-29.65-21.97-17.3-9.4
PFCF ratio
-22.45-29.41-21.61-17-9.22
P/B Ratio
674.185.614.373.52
PTB ratio
674.185.614.373.52
EV to sales
35.95056.5305.66K
Enterprise value over EBITDA
-36.69-18.21-20.03-9.04-5.12
EV to operating cash flow
-22.47-22.47-18.28-13.51-6.86
EV to free cash flow
-22.1-22.29-17.99-13.27-6.73
Earnings yield
-0.03-0.04-0.04-0.09-0.13
Free cash flow yield
-0.04-0.03-0.05-0.06-0.11
Debt to equity
0.23000.050.04
Debt to assets
0.12000.040.04
Net debt to EBITDA
0.595.824.042.541.9
Current ratio
1.9937.2721.2317.2714.25
Interest coverage
-1.32K-7.78K-14.09K-114.79K0
Income quality
1.30.811.060.670.81
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.3201.060230.69
Research and developement to revenue
1.7402.740895.75
Intangibles to total assets
00000
Capex to operating cash flow
0.020.010.020.020.02
Capex to revenue
-0.030-0.050-16.32
Capex to depreciation
-1.3-1.06-2.71-1.84-3.02
Stock based compensation to revenue
0.0100.580190.48
Graham number
2.1433.3324.332.0236.32
ROIC
-1.32-0.18-0.24-0.38-0.47
Return on tangible assets
-1.13-0.17-0.23-0.34-0.41
Graham Net
0.1416.719.999.910.23
Working capital
4.44M260.54M239.59M269.22M322.92M
Tangible asset value
5.45M261.72M243.17M277.42M332.21M
Net current asset value
3.42M260M239.36M256.41M309.48M
Invested capital
0.23000.050.04
Average receivables
461K569K9.11M9.42M966K
Average payables
1.29M2.12M2.9M3.49M4.39M
Average inventory
379.5K1.12M2.27M1.11M6.61M
Days sales outstanding
33.650326.8702.64K
Days payables outstanding
43.931.3K1.48K754.632.44K
Days of inventory on hand
15.97889.271.24K-190.076.29K
Receivables turnover
10.8501.1200.14
Payables turnover
8.310.280.250.480.15
Inventory turnover
22.860.410.29-1.920.06
ROE
-2.26-0.17-0.24-0.38-0.46
Capex per share
-0.01-0.02-0.04-0.05-0.08

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1.09-1.15-1.27-1.33-1.34
Operating cash flow per share
-0.78-1.21-1.04-1.15-0.85
Free cash flow per share
-0.8-1.24-1.05-1.16-0.86
Cash per share
10.2112.3910.889.710.99
Book value per share
10.1512.5111.029.9711.03
Tangible book value per share
10.1512.5111.029.9711.03
Share holders equity per share
10.1512.5111.029.9711.03
Interest debt per share
0.490.390.470.480.48
Market cap
1.31B1.21B1.19B945.82M1.2B
Enterprise value
1.05B873.94M881.35M672.25M881.13M
P/E ratio
-11.04-9.25-7.93-6-7.44
Price to sales ratio
000118.23K8.38K
POCF ratio
-61.2-35.38-38.58-27.83-47.05
PFCF ratio
-60.21-34.32-38.19-27.39-46.07
P/B Ratio
4.733.413.653.23.61
PTB ratio
4.733.413.653.23.61
EV to sales
00084.03K6.16K
Enterprise value over EBITDA
-35.21-24.52-23.62-15.53-22.03
EV to operating cash flow
-48.8-25.53-28.59-19.78-34.61
EV to free cash flow
-48.02-24.76-28.3-19.47-33.89
Earnings yield
-0.02-0.03-0.03-0.04-0.03
Free cash flow yield
-0.02-0.03-0.03-0.04-0.02
Debt to equity
0.050.040.040.050.04
Debt to assets
0.040.040.040.040.04
Net debt to EBITDA
8.949.478.266.327.92
Current ratio
17.2723.4320.7718.2314.25
Interest coverage
15.98K12.68000
Income quality
0.720.960.820.860.63
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0001.14K63.67
Research and developement to revenue
0004.27K262.19
Intangibles to total assets
00000
Capex to operating cash flow
0.020.030.010.020.02
Capex to revenue
000-68.75-3.78
Capex to depreciation
-2.76-6.36-1.63-2.62-2.19
Stock based compensation to revenue
0001.09K51.22
Graham number
15.7618.0317.7317.2718.21
ROIC
-0.11-0.09-0.13-0.13-0.14
Return on tangible assets
-0.1-0.09-0.11-0.12-0.11
Graham Net
9.1411.5410.078.9610
Working capital
269.22M346.76M318.21M287.73M322.92M
Tangible asset value
277.42M354.98M326.26M295.84M332.21M
Net current asset value
256.41M332.77M304.26M274.03M309.48M
Invested capital
0.050.040.040.050.04
Average receivables
493.5K993K1.05M931K994.5K
Average payables
3M4.01M4.41M4.01M4.66M
Average inventory
2.36M4.15M10.04M13.13M14.69M
Days sales outstanding
00010.1K686.64
Days payables outstanding
670.78611.58684.66631.631.99K
Days of inventory on hand
-168.951.19K1.81K2.5K5.12K
Receivables turnover
0000.010.13
Payables turnover
0.130.150.130.140.05
Inventory turnover
-0.530.080.050.040.02
ROE
-0.11-0.09-0.11-0.13-0.12
Capex per share
-0.01-0.04-0.01-0.02-0.02

KROS Frequently Asked Questions

What is Keros Therapeutics, Inc. stock symbol ?

Keros Therapeutics, Inc. is a US stock , located in Lexington of Ma and trading under the symbol KROS

Is Keros Therapeutics, Inc. buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $101.67. The lowest prediction is $80 and the highest is $120

What is KROS stock prediction ?

What is Keros Therapeutics, Inc. stock quote today ?

Keros Therapeutics, Inc. stock price is $66.1 today.

Is Keros Therapeutics, Inc. stock public?

Yes, Keros Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap